The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound of the invention inhibits JAK1 and/or JAK2 and/or JAK3 sub families. The present invention also provides methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, their tautomeric forms, and their pharmaceutically acceptable salts.本發明係關於通式(1)化合物，其為傑納斯激酶(JAK)抑制劑，傑納斯激酶係酪胺酸激酶家族，其涉及發炎狀態(inflammatory condition)、自體免疫疾病(autoimmune disease)、增生性疾病(proliferative disease)、過敏、移植排斥(transplant rejection)、涉及軟骨更新受損(impairment of cartilage turnover)之疾病、先天性軟骨畸形(congenital cartilage malformation)、及/或與IL6或干擾素過度分泌相關之疾病。尤其是，本發明之化合物抑制JAK1及/或JAK2及/或JAK3亞族。本發明亦提供製造本發明之化合物的方法，含本發明之化合物、其互變異構型、及其醫藥上可接受之鹽的醫藥組成物。
